Watch the replay of the "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy

The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients&Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T cells are then reinfused into the body with the hope of fighting the disease. To learn about this exciting new therapy, register for free HERE. Pre-registration is highly recommended.
Source: International Myeloma Foundation - Category: Hematology Source Type: news

Related Links:

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma, Published online: 15 November 2018; doi:10.1038/s41408-018-0140-1Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
(Natural News) A 67-year-old woman from London, England has reportedly put an end to her years-long battle with blood cancer with turmeric. Doctors reportedly claim to have never seen anything like this before, where medicinal plant compounds have actually cured someone’s cancer. Formally known as myeloma, this type of cancer is formed by malignant plasma...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
AbstractThe past decade has witnessed a growing role and increasing use of whole-body magnetic resonance imaging (WB-MRI). Driving these successes are developments in both hardware and software that have reduced overall examination times and significantly improved MR imaging quality. In addition, radiologists and clinicians have continued to find promising new applications of this innovative imaging technique that brings together morphologic and functional characterization of tissues. In oncology, the role of WB-MRI has expanded to the point of being recommended in international guidelines for the assessment of several can...
Source: La Radiologia Medica - Category: Radiology Source Type: research
Continuously rising trends in obesity-related malignancies render this disease spectrum a public health priority. Worldwide, the burden of cancer attributable to obesity, expressed as population attributable fraction, is 11.9% in men and 13.1% in women. There is convincing evidence that excess body weight is associated with an increased risk for cancer of at least 13 anatomic sites, including endometrial, esophageal, renal and pancreatic adenocarcinomas; hepatocellular carcinoma; gastric cardia cancer; meningioma; multiple myeloma; colorectal, postmenopausal breast, ovarian, gallbladder and thyroid cancers.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research
ConclusionsDAC treatment can inhibit myeloma cell proliferation and induce enhanced autologous T cell immune response by depleting M-MDSCs in the MM microenvironment. We believe that DAC treatment could improve the prognosis of MM in future.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Conclusiones: El tratamiento de la OMAM depende del estadio de la enfermedad; la mandibulectomía es un tratamiento efectivo en el estadio 3 y la secuestrectomía en el estadio 2; el estadio 1 suele controlarse con tratamiento conservador.ABSTRACT Introduction: Bisphosphonates are a family of drugs used to inhibit bone resorption. One of their secondary effects is osteonecrosis of the jaws (ONJ). In 2010, scientists began to publish cases of osteonecrosis of the jaws associated with a new drug, denosumab. In 2014 it was recommended to change the name of ONJ to medication-related osteonecrosis of the jaws (MONJ)...
Source: Revista Espanola de Cirugia Oral y Maxilofacial - Category: ENT & OMF Source Type: research
Authors: Tang H, Xu L, Liang X, Gao G Abstract Multiple myeloma (MM) is a hematological malignancy that lacks a cure. However, novel combination therapy is a current anti-MM strategy. Doxorubicin (DOX) is a type of anthracycline which is a first-line chemotherapeutic for treating MM and induces senescence in many types of cancer. Dinaciclib is a potent, small molecule CDK inhibitor with promise for treating several types of cancer in I/II phase clinical trials. In the present study the anticancer effects and underlying mechanisms of dinaciclib combined with DOX in MM RPMI-8226 cells were investigated. Results indic...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Zhang Z, Li Z, Chen W Abstract G protein-coupled receptor kinase 6 (GRK6) is highly expressed in multiple myeloma (MM) cell lines, but absent or only weakly expressed in most primary human somatic cells. In the present study, GRK6 expression was assessed in MM patients and healthy individuals by quantitative polymerase chain reaction. Flow cytometry were performed to measure the apoptosis of lentivial-transfected MM1R cells. Western blot analysis was performed to assess the apoptosis and signal transducer and activator of transcription 3 pathway-related factors. The results demonstrated that GRK6 was diffe...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Abstract The sialic glycoprotein, MUC1, is known to be involved in the pathogenesis of various types of cancers. KL-6 is one of the surface antigens of MUC1 and also a marker of interstitial pneumonitis. A fraction of patients with myeloma (3.9%) have elevated serum KL-6 levels without any evidence of interstitial pneumonitis and their myeloma cells have high MUC1 expression. We established a myeloma cell line designated EMM1 from a patient with multiple myeloma accompanied with elevated serum KL-6. EMM1 cells expressed high levels of MUC1 compared with other myeloma cell lines. Knockdown of MUC1 in EMM1 cells ind...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting, Published online: 09 November 2018; doi:10.1038/s41408-018-0141-0Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Hematology | Immunotherapy | Learning | Myeloma | Universities & Medical Training | University of Pennsylvania